123
123
data:image/gif;base64,R0lGODlhAQABAAD/ACwAAAAAAQABAAACADs=

Avida Biomed is Now Part of Agilent

Avida Biomed is Now Part of AgilentAvida Biomed is Now Part of AgilentAvida Biomed is Now Part of Agilent
Learn More

Avida Biomed is Now Part of Agilent

Avida Biomed is Now Part of AgilentAvida Biomed is Now Part of AgilentAvida Biomed is Now Part of Agilent
Learn More

Please visit insights.opentrons.com/ngs-automation for more information. 

App note can now be downloaded here.

About Us

Genomics in Medicine

Genome analysis has led to a new era of precision medicine. Disease-related genetic alterations can now be detected in DNA fragments circulating in the bloodstream. 

Technology

All cells shed DNA creating a tremendous opportunity for non-invasive disease detection. A single blood draw can reveal a person’s genetic predisposition to disease or even specific drug therapies. But deep knowledge requires powerful tools and precision is paramount to uncovering the genetic clues floating in our blood. We are developing novel genomic tools to reveal DNA alterations with unprecedented accuracy for clinical and research use. 

Team

Our team is passionate, experienced and looking to expand.

News Release

Conference

Avida @ AGBT 2022

Advances in Genome Biology and Technology (AGBT)

June 6- 9, 2022

https://www.agbt.org/events/general-meeting/

​

Avida Biomed to present a poster, Wednesday, June 8, 2022

Zero-PCR, UMI-independent targeted sequencing for accurate genomic profiling

Lavaging Poin-n-Seq technology, DNA target molecules are ligated to full-length sequencing adapters and captured without any amplification—before, or after enrichment. A sequencing-ready captured library is prepared with high uniformity for any intended targets in less than 4 hours. currently suitable for genotyping and genomic alteration detection in samples with adequate DNA input (>100 ng) and moderate Limit Of Detection (LOD) requirements (1%). 

​

Poster ID: #554


Avida @ ASCO 2022

American Society of Clinical Oncology (ASCO)

June 3-6, 2022. Chicago, IL

​Avida to present poster

A novel NGS kit solution for multi-cancer early detection using circulating cell free DNA based methylation analysis.


Avida @ Genomeweb 2021

GenomeWeb Report

June 9,2021

https://www.genomeweb.com/liquid-biopsy/new-liquid-biopsy-data-asco-highlights-commercial-push-early-cancer-detection#.Yjj_3erMI2w 

​

New Liquid Biopsy Data at ASCO Highlights Commercial Push Into Early Cancer Detection

Avida @ ASCO 2021

Detection of Colorectal Cancer (CRC) through Novel Dual Targeted Sequencing Solution that Enables Methylation and Genomic Alteration Analysis of Cell-Free DNA Without Sample Splitting

Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Abstract Number for Publication: 3043

Jun 4-8, 2021  


Avida @AACR 2021

Dual methylation and mutation analysis from a single input of plasma cfDNA without sample splitting

Control/Tracking Number: 21-LB-5489-AACR

Activity: Late Breaking and Clinical Trials

Category and Subclass: CL11-04 Liquid biopsies: Circulating DNA

Apr 9-14, 2021  


Avida @AGBT 2021

 Avida to present performance of Point-n-Seq Kits at AGBT poster session

Two Birds with One Stone - Novel Unified Target Sequencing Enabling Methylation and Genomic Alteration Analysis of Cell-Free DNA Without Sample Splitting

3/2/2021 12:00-2:30pm PST


Avida @ASCO 2020

Avida Biomed presented Point-N-Seq, our new liquid biopsy NGS solution at ASCO on May 29th, 2020. Point-n-Seq is the first technology that can conduct a combined methylation and genomic alteration analysis without having to split samples. With an analytical sensitivity of 0.003%, a turnaround time of just 2 days at 1/5th of the sequencing cost, Point-n-Seq is a higher performing, more cost-effective technology poised to fill the gaps in existing NGS solutions. Results from our pilot study analyzing plasma collected from CRC patients and individuals with polyps suggest that Point-n-Seq is the ideal platform solution for screening and monitoring cancer at-scale. 

https://meetinglibrary.asco.org/record/187987/abstract 

May 29-31, 2020 Virtual Meeting


Avida @AACR 2020

Avida Biomed to present promising performance data for its novel targeted methylation sequencing technology, Point-n-Seq, and pilot study of detecting early-stage cancer with plasma cfDNA at the 2020 American Association annual meeting for Cancer Research in San Diego  


Session Category:   Prevention Research 

Session Title:  Late-Breaking Research: Prevention, Early Detection, and Interception
June 22- 24, 2020
Virtual Meeting II, Sessions Available Online


Contact Us

Drop us a line!

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AVIDA Terms and Conditions of Sale 

Avida Biomed Inc.

40531 Encyclopedia Circle, Fremont, California 94538, United States

info@avidabio.com

Copyright © 2023 Avida Biomed - All Rights Reserved.

  • Terms of Sale
  • Privacy Notice

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept